CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 153 filers reported holding CYMABAY THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 0.08 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $285,661 | +36.8% | 19,159 | +0.5% | 0.00% | 0.0% |
| Q2 2023 | $208,773 | +174.7% | 19,066 | -22.9% | 0.00% | – |
| Q1 2022 | $76,000 | -17.4% | 24,721 | -8.7% | 0.00% | – |
| Q4 2021 | $92,000 | +7.0% | 27,065 | +14.6% | 0.00% | – |
| Q3 2021 | $86,000 | -34.8% | 23,622 | -22.2% | 0.00% | – |
| Q2 2021 | $132,000 | +3.9% | 30,378 | +8.3% | 0.00% | – |
| Q1 2021 | $127,000 | -14.8% | 28,039 | +7.9% | 0.00% | -100.0% |
| Q4 2020 | $149,000 | +4.9% | 25,981 | +32.6% | 0.00% | 0.0% |
| Q3 2020 | $142,000 | +100.0% | 19,592 | -4.1% | 0.00% | – |
| Q2 2020 | $71,000 | +255.0% | 20,419 | +51.4% | 0.00% | – |
| Q1 2020 | $20,000 | -57.4% | 13,485 | -44.3% | 0.00% | – |
| Q4 2019 | $47,000 | -65.2% | 24,195 | -8.5% | 0.00% | -100.0% |
| Q3 2019 | $135,000 | -28.6% | 26,444 | +0.3% | 0.00% | 0.0% |
| Q2 2019 | $189,000 | -46.6% | 26,360 | -1.2% | 0.00% | -50.0% |
| Q1 2019 | $354,000 | +71.0% | 26,682 | +1.2% | 0.00% | +100.0% |
| Q4 2018 | $207,000 | – | 26,353 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management III, LLC | 1,641,804 | $7,454,000 | 6.54% |
| COMMODORE CAPITAL LP | 2,983,513 | $13,545,000 | 5.40% |
| Foresite Capital Management IV, LLC | 1,787,094 | $8,113,000 | 0.97% |
| Avoro Capital Advisors LLC | 10,300,000 | $46,762,000 | 0.81% |
| Boxer Capital, LLC | 4,000,000 | $18,160,000 | 0.62% |
| Sio Capital Management, LLC | 562,339 | $2,553,000 | 0.52% |
| ACUTA CAPITAL PARTNERS, LLC | 315,341 | $1,432,000 | 0.52% |
| CM Management, LLC | 150,000 | $681,000 | 0.51% |
| APIS CAPITAL ADVISORS, LLC | 120,000 | $545,000 | 0.50% |
| Versant Venture Management, LLC | 543,753 | $2,469,000 | 0.48% |